People

Alan Naylor

parkinsons.org.uk

Alan Naylor is a published External Drug Discovery Adviser with the Parkinson’s Research Ventures programme. Own biography: Following a long career culminating as Vice President and Director of Medicinal Chemistry at GSK, Alan is now an independent drug discovery consultant. He is a co-inventor of Serevent (salmeterol), a marketed drug for use in asthma and chronic obstructive pulmonary disease (COPD). As a consultant, Alan has provided scientific and strategic advice to a range of academic and industrial clients and has been a member of several scientific advisory boards including membership of Wellcome Trust and Cancer Research UK committees. He is also a co-founder and adviser to Pathios Therapeutics Ltd., an Oxford-based start-up focused on immunooncology. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check. Alan Naylor is advisor - united kingdom at Brandon Capital. His Brandon advisory affiliation dates to2015. His GSK medicinal-chemistry career includes drug-discovery leadership and co-invention of salmeterol; subsequent consulting and Pathios co-founding complement his existing Parkinson’s research and Lunac advisory roles. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.